Trial Profile
A Single-blind, Multicenter, Randomized, Phase III Study of the Efficacy and Safety of Gadavist (1.0 M) in Comparison With Magnevist (0.5 M) as Contrast Agent for Enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions in Chinese Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Jun 2015
Price :
$35
*
At a glance
- Drugs Gadobutrol (Primary) ; Gadopentetic acid
- Indications Brain disorders; Spinal disorders
- Focus Diagnostic use
- Sponsors Bayer
- 11 May 2014 New trial record